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Use of the Metropolis-Hastings Algorithm 
in the Calibration of a Patient Level 
Simulation of Prostate Cancer Screening
Model Structure
A patient level simulation was implemented in Simul8,i 
dynamically linked to Excel ii  whereby the calibration 
process was run using Visual Basic. Figure 1 depicts the 
structure of the disease natural history model.














increase with age and stage of prostate cancer.





the data and their sources used to calibrate the model.








requires an understanding of 
epidemiology, disease natural history 
and screening test characteristics.
•	 	Many	of	these	aspects	of	the	decision	
problem are unobservable and data can 
only tell us about their joint uncertainty.
•	 	A	Metropolis-Hastings	algorithm	
was used to calibrate a patient level 
simulation model of the natural history 
of prostate cancer to national cancer 
registry and international trial data.
•	 	This	method	correctly	represents	
the joint uncertainty amongst the 




the probability of developing prostate 
cancer, the rate of disease progression 
and sensitivity of the screening test.
•	 	This	is	then	used	to	estimate	the	impact	
of prostate cancer screening in the UK.
•	 	This	case	study	demonstrates	that	the	
Bayesian approach to calibration can be 
used to appropriately characterise the 
uncertainty alongside computationally 
expensive simulation models.
Aim of cancer screening:
•	 	Reduce	cancer	mortality,	morbidity	






due to its unobservable nature.
•	 	Multiple	unknown	parameters	
in cancer screening model.
Solution:
•	 	Develop	loosely	parameterised	
cancer screening simulation model.
•	 	Calibrate	unobservable	model	
parameters to observed data.
•	 	Estimate	impact	of	prostate	cancer	
screening using calibrated model.
Data Source
Age	speciic	cancer	incidence UK	Oice	of	National	Statistics	(ONS)




PSA/biopsy test characteristics ERSPC3	RCT	(Rotterdam	section)
Progression Free Survival4 ERSPC3	RCT	(Rotterdam	section)
Overall Survival4 ERSPC3	RCT	(Rotterdam	section)
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Calibration Method
A	Metropolis-Hastings	algorithm	was	used	to	estimate	joint	
posterior probability distributions of model parameters. 
Figure 2 represents the iterative algorithm.



















calibration process as the parameter sets converge.
•	 	The	middle	section	depicts	how	the	total	SSE	can	
increase as the algorithm permits sets with a worse 
SSE in order that the complete parameter space is 
explored rather than stopping at a local minimum.
•	 	The	objective	is	for	the	calibration	to	converge	
to a global minimum region.
Figure 3: The total SSE during the calibration process.
Results
•	 	Figure	4	presents	plots	of	the	model	predicted	age	speciic	
incidence of prostate cancer and prostate cancer mortality under 
no organised screening against UK national statistics from 2004.
•	 	Model	predicted	age	speciic	incidence	and	prostate	
cancer mortality closely matches reported statistics.
Figure 4: Observed and modelled age speciic incidence and mortality 
of prostate cancer under no organised screening.
•	 	The	model	was	validated	against	age-	stage	and	Gleason	grade	
data from the British Association of Urological Surgeons 
(BAUS)	Cancer	Registry	for	the	year	2008	(see	Figure	5).
•	 	Model	estimated	age	and	stage	distributions	
correspond well to cancer registry data.
Figure 5: Model predicted age and stage distributions of prostate cancer  
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Conclusion
Parameterising complex conceptual models containing 
unobservable elements is a challenging process.
A	Metropolis-Hastings	algorithm	was	used	to	calibrate	
these unobservable model parameters such that model 
outputs were comparable with observed data.
This	Bayesian	approach	to	calibration	has	wider	
applications than health, and can be used to appropriately 
characterise	uncertainty	in	other	ields	including	within	
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Impact of Screening in the UK
The	cost-efectiveness	of	diferent	
screening options is currently being 
investigated	on	behalf	of	the	UK	National	
Screening	Committee	using	the	calibrated	
model. Preliminary results suggest that 
single screening strategies have little 
impact	on	overall	age	speciic	prostate	
cancer incidence and mortality rates. Any 
overall	survival	beneit	is	likely	to	be	small;	
approximately 1 day for single screening 
strategies and 11 days for repeat screening.
